The U.S. osteoporosis drugs market will reach USD 9,105.2 million by 2030, growing at a CAGR of 4.90%. Similarly, the EU osteoporosis drugs market revenue will be USD 4,265.4 million by the end of this decade, with a 4.65% CAGR, as stated by P&S Intelligence.
 |
| To learn more about this report: https://bit.ly/3M6v0eG |
The growth is attributed to the growing incidence rate of osteoporosis, the mounting geriatric population, the surging obesity cases, the expanding occurrence of lifestyle- diseases, and the escalating healthcare expenditure in the U.S. and the EU.
On the basis of type, the bisphosphonates category had the largest revenue share, and it will maintain its ascendency in the years to come. This is because bisphosphonates have proved efficiency to minimalize fracture risk at the spine, hip and other non-vertebral skeletal sites, surge the survival rate, and decrease the considerable risk of morbidity.
Furthermore, the increasing count of women in the post-menopausal stage and an increase in the occurrence of bone diseases will further contribute to the requirement for these kinds of drugs.
The U.S. osteoporosis drugs market has a higher share of revenue and it will maintain its dominance in the future, and the EU osteoporosis drugs market will grow at a significant rate as stated by P&S Intelligence.
This is as a result of the high incidence rate of bone-related ailments and osteoporosis-related fractures, the increasing count of clinics and hospitals, the increasing government investment for emerging cutting-edge healthcare infra, and the growing number of consciousness programs.
It is because of the increasing prevalence of osteoporosis, the demand for osteoporosis drugs will continue to increase in the U.S. and EU.
